A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Clinical trial NCT05756777 · RECRUITING
Trial details
- NCT number
- NCT05756777
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-25
- Primary completion
- 2027-04-21
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.